How Cancer Research Horizons is building the future of childhood cancer medicines
Cancer Research Horizons' CBO Tony Hickson discusses why charity and pharma need each other now more than ever. The post How Cancer Research Horizons is building the future of childhood cancer medicines appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner…
Welcome to the official Labiotech.eu podcast - Beyond Biotech. Each week, we discuss developments in the biotech world through news and interviews with industry experts. Our host is Dylan Kissane.
This episode features Tony Hickson, Chief Business Officer for Cancer Research Horizons, a division of Cancer Research UK. He explains how the organization is transforming early-stage cancer research into new treatments, diagnostics, and start-up companies.
Despite being the leading cause of death by disease in children and young people, only a small number of drugs have been approved specifically for pediatric cancer. Most treatments for children are simply repurposed adult drugs, often leading to long-term negative consequences.
Tony Hickson discusses why charity and pharmaceutical companies must collaborate more closely. He also introduces C-Further, a significant initiative aimed at developing medicines specifically tailored for children, rather than simply adapted from adult treatments.
Written by urgent.news from Labiotech's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
